Financial Reports Latest Updates Industry Maps Economic Calendar

Coherus Oncology, Inc. (CHRS) Annual Reports

Q: Where can I read Coherus Oncology, Inc. (CHRS) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Coherus Oncology, Inc. is listed on Nasdaq, classified by the SEC under Biological Products, (No Diagnostic Substances) (SIC 2836). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1512762 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$14.3M	$10.3M	+39.5%
Operating income	$-32.3M	$-45.5M	+28.9%
Net income	$-20.6M	$297.8M	-106.9%
EPS (diluted)	$-0.13	$2.57	-105.1%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 14.3 mn Net income -20.6 mn

Show table：Income statement

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	1.90	0.51	0.51	0.51	1.23	3.60	4.97	16.1	6.49	5.81	6.87	7.17	10.2	12.4	14.1	163	0.84	0.16	1.40	0	0	0	0	0	0	37.1	83.4	112	124	116	136	114	110	83.0	87.6	82.5	73.4	60.1	60.1	45.4	45.4	32.4	58.7	74.6	91.5	77.1	65.0	70.8	54.1	7.60	10.3	11.6	12.8	12.3	14.3
Gross profit	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	34.9	82.8	105	116	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating income	-38.5	—	—	-6.78	-10.5	-13.8	-17.9	-6.42	-26.6	-36.8	-58.9	-71.2	-52.2	-64.3	-62.7	84.6	-73.5	-72.4	-56.6	-56.6	-46.5	-42.0	-44.9	-57.0	-60.5	-16.6	27.5	51.8	45.0	40.9	65.3	33.7	16.4	-167	-24.2	-32.8	-39.5	-80.9	-44.0	-80.5	-51.5	-67.7	-34.5	-32.0	-68.9	-42.5	-20.5	-6.39	-42.3	-45.4	-45.5	-44.3	-45.9	-36.1	-32.3
Net income	-33.0	-8.86	-8.71	-21.5	-14.6	-25.2	-25.0	-7.87	-29.1	-40.7	-58.8	-71.3	-52.4	-65.4	-70.0	83.9	-75.9	-74.8	-55.3	-59.0	-49.1	-44.3	-43.6	-58.8	-62.6	-20.0	23.6	47.0	39.2	35.6	59.0	27.9	9.71	-173	-29.9	-38.5	-45.7	-96.1	-50.1	-86.7	-58.9	-75.7	-42.9	-39.6	-79.7	103	-12.9	-10.8	-50.7	-56.6	298	-35.5	-37.6	-38.3	-20.6

Balance sheet

Quarterly · In mn (USD)

Total assets 191 mn Total liabilities 130 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	45.7	—	—	119	179	144	240	189	197	212	237	177	161	208	153	172	145	112	173	130	84.4	159	206	276	343	395	676	727	767	617	660	673	602	512	447	448	381	316	385	444	476	627	558	369	342	310	380	461	207	206	134
Total assets	—	—	—	—	47.5	—	—	129	187	153	250	202	212	226	251	192	178	228	172	190	163	128	188	141	99.5	186	240	327	409	467	757	804	842	693	740	742	679	593	546	551	481	402	470	584	630	764	675	505	449	371	439	517	258	266	191
Current liabilities	—	—	—	—	53.7	—	—	48.1	51.8	51.9	70.0	82.5	106	92.9	108	58.4	56.4	47.3	36.0	31.4	28.4	27.6	22.2	24.5	33.3	41.4	61.2	82.7	115	119	130	133	146	258	287	320	165	154	141	171	139	123	169	240	332	538	463	296	283	255	264	372	140	132	75.5
Total liabilities	—	—	—	—	89.8	—	—	120	120	115	153	162	219	293	313	161	159	151	141	135	132	132	126	129	138	225	244	271	304	309	543	548	561	566	583	611	582	581	569	648	618	599	644	717	823	845	759	593	581	555	320	429	197	187	130
Equity	-45.5	—	—	—	-97.1	—	—	-152	66.8	38.1	96.8	40.6	-6.21	-66.0	-60.9	32.9	20.5	78.2	32.1	56.2	31.8	-1.79	63.2	12.4	-38.6	-38.5	-3.98	56.0	105	157	213	256	281	128	156	131	97.7	12.6	-22.6	-97.1	-137	-197	-175	-134	-193	-81.8	-84.1	-88.0	-132	-183	120	87.8	61.0	78.6	60.8

Cash flow

Quarterly · In mn (USD)

Operating -62.1 mn Investing 29.6 mn Financing 0.14 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-18.3	—	—	10.4	4.99	14.8	-0.22	-5.17	-33.3	-33.1	-20.8	-59.6	5.57	-76.3	-27.4	-62.0	-86.9	-73.3	-55.6	-41.5	-29.9	-33.6	-35.5	-42.8	-47.4	-57.0	12.7	55.0	17.7	13.5	60.2	47.4	33.1	1.37	-0.19	13.7	-52.3	-54.0	-50.0	-37.1	-100.0	-68.7	-38.9	-54.3	-12.9	-46.8	59.7	-62.0	28.6	-25.8	-46.6	-46.3	-19.7	-57.9	-62.1
Investing	-1.82	—	—	-0.22	-0.15	2.07	-1.29	-0.81	-0.5	-1.31	-1.01	-3.18	-1.44	-2.15	-0.3	-0.5	-3.57	-51.6	4.06	28.7	14.4	-13.2	-16.6	12.8	15.8	-15.2	8.82	-0.29	-6.06	-1.62	-239	16.4	210	-285	23.6	16.0	107	-35.6	-0.88	-0.46	-130	17.5	41.4	50.5	35.2	203	27.7	0.44	-0.54	-17.5	463	-67.2	-2.84	30.7	29.6
Financing	26.9	—	—	9.96	0	0.01	54.0	-1.78	83.8	-0.73	113	10.5	0.33	99.8	69.1	1.25	56.0	125	-0.18	75.1	6.89	1.88	99.9	1.06	2.59	81.5	3.01	3.68	1.20	3.92	210	4.09	5.51	2.44	46.9	1.10	1.49	-1.85	0.72	48.9	6.59	3.80	54.3	11.1	0.37	0.89	-188	-0.17	0.23	-0.26	-282	0	8.08	53.6	0.14
Cash at period end	14.6	—	—	34.7	39.5	56.3	109	101	150	115	206	154	158	180	221	160	125	125	73.3	136	127	82.0	130	101	72.4	81.5	106	165	178	193	225	292	541	259	330	361	417	326	275	287	63.5	16.1	72.9	80.3	103	260	159	97.7	126	82.4	217	103	88.9	115	82.9

Profitability

Quarterly · %

Gross margin 93.7% Operating margin -226.0% Net margin -144.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Gross margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	94.0%	99.3%	94.2%	93.7%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating margin	-2028.3%	—	—	-1340.5%	-851.2%	-382.7%	-361.3%	-40.0%	-409.1%	-632.5%	-857.8%	-993.7%	-511.9%	-520.7%	-445.9%	52.0%	-8703.8%	-44979.5%	-4060.1%	—	—	—	—	—	—	-44.7%	33.0%	46.4%	36.4%	35.2%	48.1%	29.7%	14.9%	-201.6%	-27.6%	-39.7%	-53.9%	-134.6%	-73.2%	-177.1%	-113.5%	-208.9%	-58.8%	-42.9%	-75.3%	-55.2%	-31.6%	-9.0%	-78.0%	-597.9%	-443.6%	-383.1%	-359.9%	-293.7%	-226.0%
Net margin	-1738.7%	-1751.4%	-1717.8%	-4243.7%	-1184.3%	-699.9%	-502.7%	-49.0%	-448.7%	-701.0%	-856.5%	-995.3%	-513.7%	-529.1%	-497.4%	51.5%	-8995.4%	-46446.0%	-3966.7%	—	—	—	—	—	—	-53.9%	28.3%	42.1%	31.7%	30.6%	43.5%	24.6%	8.8%	-208.3%	-34.1%	-46.7%	-62.3%	-159.8%	-83.4%	-190.8%	-129.8%	-233.5%	-73.0%	-53.2%	-87.0%	133.5%	-19.9%	-15.2%	-93.6%	-744.4%	2903.9%	-307.1%	-295.3%	-311.4%	-144.2%

Returns & leverage

Quarterly · %

ROE -146.3% ROA -41.9% Debt ratio 68.2%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	—	-269.2%	-141.1%	—	-736.9%	—	-1445.2%	-282.7%	-1778.5%	-2246.9%	—	-595.1%	-909.9%	-543.8%	-411.3%	-571.0%	—	—	-398.2%	-35.0%	269.7%	244.9%	172.8%	103.8%	68.5%	-53.5%	-89.4%	-119.9%	-151.6%	-299.8%	-345.1%	-1657.1%	—	—	—	—	—	—	—	—	—	—	1006.5%	—	—	—	-146.3%
ROA	—	—	—	—	-113.0%	—	—	-56.2%	-74.3%	-67.0%	-54.7%	-120.7%	-111.7%	-130.7%	-103.5%	-52.6%	-65.2%	-60.3%	-57.7%	-138.7%	-139.7%	-116.7%	-108.7%	-118.2%	-159.8%	-117.7%	-55.0%	-5.1%	35.3%	44.6%	36.3%	28.6%	21.1%	-13.2%	-22.1%	-30.0%	-37.8%	-32.7%	-35.9%	-43.1%	-50.3%	-54.5%	-52.0%	-38.3%	-42.9%	-10.2%	-5.1%	-0.1%	5.3%	-23.1%	32.3%	30.3%	47.5%	58.5%	-41.9%
Debt ratio	—	—	—	—	189.3%	—	—	92.9%	64.3%	75.2%	61.4%	80.2%	103.3%	129.6%	124.7%	83.5%	89.2%	66.2%	82.1%	71.1%	81.2%	102.4%	67.2%	91.2%	138.8%	120.7%	101.7%	82.9%	74.3%	66.3%	71.8%	68.2%	66.6%	81.6%	78.9%	82.4%	85.6%	97.9%	104.1%	117.6%	128.6%	148.8%	137.2%	122.9%	130.7%	110.7%	112.5%	117.4%	129.4%	149.4%	72.7%	83.0%	76.4%	70.4%	68.2%

EPS

Quarterly · US$

EPS US$-0.13

Show table：EPS

Item	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	-1.86	—	-1.67	-1.72	1.67	-1.71	—	—	-1.09	-0.80	—	-0.68	-0.87	-0.83	-0.29	0.32	0.63	0.53	0.48	0.70	0.33	0.10	-2.37	-0.40	-0.49	-0.59	-1.24	-0.65	-1.11	-0.76	-0.96	-0.49	-0.41	-0.74	0.83	-0.11	-0.09	-0.40	-0.49	2.57	-0.31	-0.34	-0.28	-0.13

Revenue & profit

Year-to-date · In mn (USD)

Revenue 26.6 mn Net income -59.0 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 191 mn Total liabilities 130 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -120 mn Investing 60.3 mn Financing 53.7 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Gross margin 95.2% Operating margin -257.3% Net margin -221.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -146.3% ROA -41.9% Debt ratio 68.2%

EPS

Year-to-date · US$

EPS US$-0.41

Revenue & profit

Annual · In mn (USD)

Revenue 42.2 mn Net income 168 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	2.75	31.1	30.0	190	1.56	0	356	476	327	211	257	267	42.2
Gross profit	—	—	—	—	—	—	339	—	—	—	—	—	—
Operating income	—	-64.7	-219	-116	-232	-204	108	156	-264	-257	-203	-112	-181
Net income	-53.6	-87.1	-223	-127	-238	-209	89.8	132	-287	-292	-238	28.5	168

Balance sheet

Annual · In mn (USD)

Total assets 258 mn Total liabilities 197 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	45.7	179	197	161	145	84.4	343	767	602	381	476	342	207
Total assets	47.5	187	212	178	163	99.5	409	842	679	481	630	449	258
Current liabilities	53.7	51.8	106	56.4	28.4	33.3	115	146	165	139	332	283	140
Total liabilities	89.8	120	219	159	132	138	304	561	582	618	823	581	197
Equity	-97.1	66.8	-6.21	20.5	31.8	-38.6	105	281	97.7	-137	-193	-132	61.0

Cash flow

Annual · In mn (USD)

Operating -139 mn Investing 375 mn Financing -274 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-23.9	-108	-253	-200	-159	28.4	154	-37.4	-241	-175	-20.4	-139
Investing	—	-0.52	-6.95	-6.51	-4.42	-1.19	-12.7	-14.4	-138	-167	145	230	375
Financing	—	136	123	226	207	105	89.4	224	51.9	54.3	69.6	-187	-274
Cash at period end	39.5	150	158	125	127	72.4	178	541	417	63.5	103	126	88.9

Profitability

Annual · %

Gross margin 95.2% Operating margin -429.5% Net margin 398.4%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Gross margin	—	—	—	—	—	—	95.2%	—	—	—	—	—	—
Operating margin	—	-207.9%	-729.2%	-61.0%	-14918.8%	—	30.3%	32.9%	-80.8%	-121.7%	-79.0%	-41.8%	-429.5%
Net margin	-1949.7%	-280.1%	-743.2%	-67.0%	-15306.6%	—	25.2%	27.8%	-87.9%	-138.2%	-92.5%	10.7%	398.4%

Returns & leverage

Annual · %

ROE -151.6% ROA 47.5% Debt ratio 76.4%

Show table：Returns & leverage

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	—	-736.9%	-1778.5%	-909.9%	—	269.7%	68.5%	-151.6%	—	—	—	—
ROA	-113.0%	-74.3%	-111.7%	-65.2%	-139.7%	-159.8%	35.3%	21.1%	-37.8%	-50.3%	-42.9%	5.3%	47.5%
Debt ratio	189.3%	64.3%	103.3%	89.2%	81.2%	138.8%	74.3%	66.6%	85.6%	128.6%	130.7%	129.4%	76.4%

EPS

Annual · US$

EPS US$1.43

Show table：EPS

Item	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	-3.43	—	—	1.19	1.61	-3.85	-3.76	-2.60	0.23	1.43

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Coherus Oncology, Inc. (CHRS) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.